New compound classes: Protein–protein interactions

C. Ottmann

doi:10.1007/164_2015_30

New compound classes: Protein–protein interactions

C. Ottmann

Chemical Biology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

6 Citations (Scopus)

9 Downloads (Pure)

Abstract

Protein-protein interactions (PPIs) are one of the most promising new targets in drug discovery. With estimates between 300,000 and 650,000 in human physiology, targeted modulation of PPIs would tremendously extend the "druggable" genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number of success stories in small-molecule PPI inhibition and natural-product PPI stabilization increasingly encourage academia and industry to invest in PPI modulation. In this chapter examples of both inhibition as well as stabilization of PPIs are reviewed including some of the technologies which has been used for their identification

Original language	English
Title of host publication	Handbook of Experimental Pharmacology
Editors	U. Nielsch, U. Fuhrmann, S. Jaroch
Place of Publication	Berlin
Publisher	Springer
Pages	125-138
Number of pages	14
ISBN (Electronic)	978-3-319-28914-4
ISBN (Print)	978-3-319-28912-0
DOIs	https://doi.org/10.1007/164_2015_30
Publication status	Published - 1 Apr 2016

Publication series

Name	Handbook of experimental pharmacology
Publisher	Springer
Volume	232
ISSN (Print)	0171-2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Natural products
PPI inhibition
PPI stabilization
Small-molecules
X-ray crystallography

Access to Document

10.1007/164_2015_30

Cite this

@inbook{e39b0cd879df4f5f9eb46890e7ccc202,

title = "New compound classes: Protein–protein interactions",

abstract = "Protein-protein interactions (PPIs) are one of the most promising new targets in drug discovery. With estimates between 300,000 and 650,000 in human physiology, targeted modulation of PPIs would tremendously extend the {"}druggable{"} genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number of success stories in small-molecule PPI inhibition and natural-product PPI stabilization increasingly encourage academia and industry to invest in PPI modulation. In this chapter examples of both inhibition as well as stabilization of PPIs are reviewed including some of the technologies which has been used for their identification",

keywords = "Natural products, PPI inhibition, PPI stabilization, Small-molecules, X-ray crystallography",

author = "C. Ottmann",

year = "2016",

month = apr,

day = "1",

doi = "10.1007/164\_2015\_30",

language = "English",

isbn = "978-3-319-28912-0",

series = "Handbook of experimental pharmacology",

publisher = "Springer",

pages = "125--138",

editor = "U. Nielsch and U. Fuhrmann and S. Jaroch",

booktitle = "Handbook of Experimental Pharmacology",

address = "Germany",

}

TY - CHAP

T1 - New compound classes

T2 - Protein–protein interactions

AU - Ottmann, C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Protein-protein interactions (PPIs) are one of the most promising new targets in drug discovery. With estimates between 300,000 and 650,000 in human physiology, targeted modulation of PPIs would tremendously extend the "druggable" genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number of success stories in small-molecule PPI inhibition and natural-product PPI stabilization increasingly encourage academia and industry to invest in PPI modulation. In this chapter examples of both inhibition as well as stabilization of PPIs are reviewed including some of the technologies which has been used for their identification

AB - Protein-protein interactions (PPIs) are one of the most promising new targets in drug discovery. With estimates between 300,000 and 650,000 in human physiology, targeted modulation of PPIs would tremendously extend the "druggable" genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number of success stories in small-molecule PPI inhibition and natural-product PPI stabilization increasingly encourage academia and industry to invest in PPI modulation. In this chapter examples of both inhibition as well as stabilization of PPIs are reviewed including some of the technologies which has been used for their identification

KW - Natural products

KW - PPI inhibition

KW - PPI stabilization

KW - Small-molecules

KW - X-ray crystallography

UR - https://www.scopus.com/pages/publications/84962695557

U2 - 10.1007/164_2015_30

DO - 10.1007/164_2015_30

M3 - Chapter

C2 - 26489828

AN - SCOPUS:84962695557

SN - 978-3-319-28912-0

T3 - Handbook of experimental pharmacology

SP - 125

EP - 138

BT - Handbook of Experimental Pharmacology

A2 - Nielsch, U.

A2 - Fuhrmann, U.

A2 - Jaroch, S.

PB - Springer

CY - Berlin

ER -

New compound classes: Protein–protein interactions

Abstract

Publication series

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this